An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease

Stopped early · Phase 3

Conditions studied: Alzheimer's Disease

In brief

The purpose of this study is to evaluate the long-term safety and tolerability of dimebon in subjects with moderate-to-severe Alzheimer's Disease.

Key facts

Study ID

NCT01066546

Run by

Pfizer

People needed

5

Starts

2010-04-01

Expected to finish

2010-07-01

Last updated by the study team

2012-10-02

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Successful completion of 6 months treatment in the previous B1451006 Phase 3 dimebon study

You may not qualify if…

• Any major medical illness or unstable medical condition that may increase the risk associated with study participation or investigational product administration or may interfere with the ability to interpret study safety data

Where it is running

• Pfizer Investigational Site — Costa Mesa, California, United States
• Pfizer Investigational Site — Encino, California, United States
• Pfizer Investigational Site — Los Alamitos, California, United States
• Pfizer Investigational Site — Newport Beach, California, United States
• Pfizer Investigational Site — Delray Beach, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.